Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 481 AL 495

Assessing an evidence-based intervention for spouse caregivers of persons with Alzheimer's disease: results of a community implementation of the NYUCI in Israel

Werner P, Clay OJ, Goldstein D, Kermel-Schifmann I, Herz MK, Epstein C, Mittelman MS.

Aging Ment Health. 2021 Sep;25(9):1676-1683. doi: 10.1080/13607863.2020.1774740. Epub 2020 Jun 4.

Inter-individual differences in the responses to aerobic exercise in Alzheimer's disease: Findings from the FIT-AD trial

Yu F, Salisbury D, Mathiason MA.

J Sport Health Sci. 2021 Jan;10(1):65-72. doi: 10.1016/j.jshs.2020.05.007. Epub 2020 Jun 4.

From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology

Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML.

Med Res Rev. 2021 Sep;41(5):2606-2633. doi: 10.1002/med.21699. Epub 2020 Jun 19.

Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease

Shevtsova EF, Maltsev AV, Vinogradova DV, Shevtsov PN, Bachurin SO.

Med Res Rev. 2021 Mar;41(2):803-827. doi: 10.1002/med.21715. Epub 2020 Jul 20.

Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort

Abdeljalil AB, de Mauléon A, Baziard M, Vellas B, Lapeyre-Mestre M, Soto M.

J Am Med Dir Assoc. 2021 Feb;22(2):433-439. doi: 10.1016/j.jamda.2020.06.028. Epub 2020 Jul 28.

A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

Gadhave K, Kumar D, Uversky VN, Giri R.

Med Res Rev. 2021 Sep;41(5):2689-2745. doi: 10.1002/med.21719. Epub 2020 Aug 11.

Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood-Brain Barrier for Effective Treatment of Alzheimer's Disease

Arora S, Layek B, Singh J.

Mol Pharm. 2021 Feb 1;18(2):714-725. doi: 10.1021/acs.molpharmaceut.0c00461. Epub 2020 Sep 16.

Expanded access: opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases

Özdinler PH.

FEBS J. 2021 Mar;288(5):1457-1461. doi: 10.1111/febs.15529. Epub 2020 Sep 5.

Novel Targets for Alzheimer's Disease: A View Beyond Amyloid

Ray WJ, Buggia-Prevot V.

Annu Rev Med. 2021 Jan 27;72:15-28. doi: 10.1146/annurev-med-052919-120219. Epub 2020 Aug 31.

Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery

Zameer S, Ali J, Vohora D, Najmi AK, Akhtar M.

J Drug Target. 2021 Feb;29(2):199-216. doi: 10.1080/1061186X.2020.1817041. Epub 2020 Sep 10.

Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease

Kent BA, Feldman HH, Nygaard HB.

Prog Neurobiol. 2021 Feb;197:101902. doi: 10.1016/j.pneurobio.2020.101902. Epub 2020 Aug 30.

Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets

Uddin MS, Al Mamun A, Kabir MT, Ashraf GM, Bin-Jumah MN, Abdel-Daim MM.

Mol Neurobiol. 2021 Jan;58(1):281-303. doi: 10.1007/s12035-020-02116-9. Epub 2020 Sep 15.

Tubulin modifying enzymes as target for the treatment of tau-related diseases

Rogowski K, Hached K, Crozet C, van der Laan S.

Pharmacol Ther. 2021 Feb;218:107681. doi: 10.1016/j.pharmthera.2020.107681. Epub 2020 Sep 19.

One call makes a difference: An evaluation of the Alzheimer's Association National Helpline on dementia caregiver outcomes

Hodgson NA, Petrovsky DV, Finegan K, Kallmyer BA, Pike J, Fazio S.

Patient Educ Couns. 2021 Apr;104(4):896-902. doi: 10.1016/j.pec.2020.09.026. Epub 2020 Sep 23.

Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)

Rombouts F, Kusakabe KI, Hsiao CC, Gijsen HJM.

Expert Opin Ther Pat. 2021 Jan;31(1):25-52. doi: 10.1080/13543776.2021.1832463. Epub 2020 Dec 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias